6 results
Currently, all rotigotine transdermal patches are manufactured at 1 manufacturing site. A second site has been built to manufacture the same patches. Before these patches may be used, it needs to be investigated if they are exactly the same as those…
In this study we want to investigate the clinical and cost-effectiveness of internet-based VR, with and without physiotherapeutic support, for older dizzy patients in general practice in comparison with usual care. Furthermore, we want to identify…
Primary objective• To evaluate efficacy of acalabrutinib/venetoclax (AV) in terms of undetectable minimal residual disease (uMRD) response in bone marrow (BM) after 26 cycles of treatment in patients with CLL previously treated with venetoclax and…
The aim is thereby to reduce the risk of serious infections and the need for regular CLL treatment.
Primary objective: To determine the efficacy of the combination of acalabrutinib and venetoclax without obinutuzumab (AV; Arm A), or with obinutuzumab (AVG; Arm B) compared with chemoimmunotherapy (fludarabine/cyclophosphamide/rituximab [FCR]/…
Therapy:The investigational product, ACP-196, will be supplied as hardgelatin capsules for oral administration.Commercially available ibrutinib (IMBRUVICA®) will be used asthe reference therapy.Objectives: Primary Objective:To assess whether ACP-196…